Susan Hoover presented new research findings at the American Society of Microbiology (ASM) Microbe conference in Atlanta, GA. Dr. Hoover, along with biostatistician Jing Zhao, analyzed clinical diagnosis and management decisions on patients with Clostridium difficile, the most common healthcare-associated infection in the U.S. "Clostridium difficile testing affects the treatment decision"
Susan Hoover attended the annual Coccidioidomycosis Study Group meeting in Flagstaff, AZ. This research group discusses the pathogenesis, mycology and clinical aspects of Coccidioidomycosis, a fungal infection responsible for Valley fever. Dr. Hoover served on the program committee and as a session moderator
Dr. Susan Hoover was invited by the American Board of Internal Medicine to participate in the standard setting process for the Infectious Disease board exam. This process determines the passing score on the exams.
Dr. Hoover’s proposal for analysis of the care of patients with Clostridium difficile infection was accepted by the Sanford Data Collaborative.
Dr. Hoover co-authored a paper describing the development of a new test for Valley Fever. The paper is titled “Enhanced antibody detection and diagnosis of coccidioidomycosis with the MiraVista IgG and IgM detection enzyme immunoassay”. https://www.ncbi.nlm.nih.gov/pubmed/28053216
Dr. Susan Hoover was quoted in an article about valley fever by the Center for Health Journalism Collaborative.http://tucson.com/news/accurate-valley-fever-counts-elude-health-officials/article_ad2a08ce-3d6a-515d-af78-cb18489f07c3.html